A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Another immuno-oncology mechanism threatens to disappoint
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.
Squelgene does a lopsided swap with Jounce
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
Gilead-Galapagos deal rescues a slow licensing year
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.
Through Gilead, Galapagos secures an independent future
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Redx sells another asset to keep the lights on
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
As Genfit deals and Conatus folds, Nash plays on
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Time to restock big pharma’s leaking pipeline
The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.
Who will capitalise on CAR-T at last? Not big pharma, says Tmunity
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.